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Parasites are widely distributed throughout the world and
represent an important cause of morbidity and mortality, mainly
in tropical and subtropical regions.1 Most of those parasites
exist and persist for social and economic reasons that enable
pathogens to take advantage of changes in behavioral and physical
environments.
Giardia duodenalis (also known as Giardia lamblia and Giardia
intestinalis) is the most common intestinal pathogenic protozoan
infection reported in humans, and the disease it causes, giardiasis,
is now included in the neglected diseases initiative. Approximately
280 million people are infected each year with this parasite, but
this estimation could be low considering that infection rates are
higher in endemic countries where diagnostic facilities and
reporting systems are unavailable or not functional.
The lack of any useful parasite vaccine means that prevention of
this and many other parasitic diseases continues to be based on
ecologic measures aimed at interrupting the biological cycle of the
parasite combined with the use of antiparasitic drugs.
Mebendazole (MBZ) has been used worldwide because of its
relatively poor absorption from the intestine, low level of adverse
events, and broad spectrum of action against soil-transmitted
helminths, even in single doses. The low cost, effectiveness, lack
of action on intestinal microbiota, and the safety of this drug
further enhances its therapeutic appeal. MBZ has been evaluated for
its potential use against protozoan and helminth infections other
than the common soil-transmitted helminths, providing some
evidence that encourages scientists to use it in certain situations,
such as for cases of treatment failure or resistance.2
Some in vitro studies have demonstrated MBZ activity against G
duodenalis infection. The authors of these studies showed that this
drug affects the growth of the protozoa, inducing trophozoite
detachment and distortion of both morphology and general
structure.7–10
Based on these in vitro studies, our group carried out 4 clinical
trials in Cuba—3 in children and 1 in adults—evaluating the
efﬁcacy and safety proﬁle of MBZ in the treatment of G duodenalis.
These studies offered clear evidence of the effectiveness and
tolerability of MBZ to treat G duodenalis.3–6
Three days’ treatment with MBZ was similar in efﬁcacy to the
ﬁrst-line drugs used for the treatment of giardiasis, both in
children and in adult patients.
After 8 years of extensive clinical use, we have found MBZ (200
mg 3 times daily for 3 days)3 to be excellent in treating children
aged 5 to 15 years mono infected with G duodenalis. From the
beginning of 2008 to the end of 2015, of 522 children attending thex.doi.org/10.1016/j.curtheres.2016.03.001
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ment for this intestinal protozoa, 450 (86.2%) were healed. The
efﬁcacy of the chemotherapy was assessed by microscopic exam-
ination (as direct wet mounts and after formol–ether concentra-
tion) of fecal samples collected soon (ie, 3, 5, and 7 days) after
treatment completion, to avoid the bias that would be introduced
by reinfection. A child was only considered cured if no Giardia
trophozoites or cysts could be found in any of the 3 posttreatment
fecal specimens.
The drug was well tolerated. Only mild, transient, and self-
limited side effects were reported and these did not require
discontinuation of treatment. Abdominal pain (29 out of 522
patients; 5.6%), nausea (15 out of 522 patients; 2.9%), and vomiting
(12 out of 522 patients; 2.3%) were the only side effects reported.
Additionally, from 2010 to the end of 2015, 423 adults mono
infected by G duodenalis were also treated successfully using MBZ
(200 mg 3 times daily for 3 days).6 Similar to the children group,
MBZ was an exceptional option. Of 423 patients treated, 392
(92.7%) were cured. In this group the only adverse effect reported
was abdominal pain in 26 out of 423 patients (6.2%).
The effective management of G duodenalis infection has been
considered problematic, especially in tropical and subtropical
areas. Based on our clinical trials as well as anecdotal experience,
MBZ could be an excellent alternative in the treatment of
G duodenalis infections both in children and in adults.Acknowledgment
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